Fulgent Genetics, Inc. (NASDAQ: FLGT) Stock Competitors & Peer Comparison
See FLGT's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for FLGT and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| FLGT | $20.22 | +0.60% | 556.4M | 2022.00 | $0.01 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.66% |
| TMO | $684.89 | +1.64% | 253.2B | 29.56 | $23.16 | +0.27% |
| DHR | $232.97 | +1.07% | 163.8B | 29.19 | $7.98 | +0.66% |
| NTRA | $404.90 | +0.24% | 58.4B | -306.74 | -$1.32 | N/A |
| A | $175.96 | +1.67% | 49.6B | 30.28 | $5.81 | +0.58% |
| IQV | $273.60 | -2.06% | 45B | 22.55 | $12.13 | N/A |
| IDXX | $570.21 | +1.75% | 44.9B | 40.10 | $14.22 | N/A |
| WAT | $455.98 | +0.51% | 44.8B | 33.33 | $13.68 | N/A |
| ILMN | $271.04 | +0.60% | 40.9B | 53.88 | $5.03 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
FLGT vs DHR-PB Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, FLGT's ROE is -0.08%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, FLGT is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
FLGT vs TMO Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, TMO has a market cap of 253.2B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while TMO trades at $684.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas TMO's P/E ratio is 29.56. In terms of profitability, FLGT's ROE is -0.08%, compared to TMO's ROE of +0.13%. Regarding short-term risk, FLGT is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
FLGT vs DHR Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, DHR has a market cap of 163.8B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while DHR trades at $232.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas DHR's P/E ratio is 29.19. In terms of profitability, FLGT's ROE is -0.08%, compared to DHR's ROE of +0.08%. Regarding short-term risk, FLGT is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
FLGT vs NTRA Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, NTRA has a market cap of 58.4B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while NTRA trades at $404.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas NTRA's P/E ratio is -306.74. In terms of profitability, FLGT's ROE is -0.08%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, FLGT is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
FLGT vs A Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, A has a market cap of 49.6B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while A trades at $175.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas A's P/E ratio is 30.28. In terms of profitability, FLGT's ROE is -0.08%, compared to A's ROE of +0.20%. Regarding short-term risk, FLGT is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
FLGT vs IQV Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, IQV has a market cap of 45B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while IQV trades at $273.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas IQV's P/E ratio is 22.55. In terms of profitability, FLGT's ROE is -0.08%, compared to IQV's ROE of +0.22%. Regarding short-term risk, FLGT is less volatile compared to IQV. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check IQV's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
FLGT vs IDXX Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, IDXX has a market cap of 44.9B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while IDXX trades at $570.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas IDXX's P/E ratio is 40.10. In terms of profitability, FLGT's ROE is -0.08%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, FLGT is less volatile compared to IDXX. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check IDXX's competition here
Waters Corporation (NYSE: WAT)
FLGT vs WAT Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, WAT has a market cap of 44.8B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while WAT trades at $455.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas WAT's P/E ratio is 33.33. In terms of profitability, FLGT's ROE is -0.08%, compared to WAT's ROE of +0.02%. Regarding short-term risk, FLGT is less volatile compared to WAT. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check WAT's competition here
Illumina, Inc. (NASDAQ: ILMN)
FLGT vs ILMN Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, ILMN has a market cap of 40.9B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while ILMN trades at $271.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas ILMN's P/E ratio is 53.88. In terms of profitability, FLGT's ROE is -0.08%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, FLGT is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
FLGT vs MTD Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, MTD has a market cap of 33.5B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while MTD trades at $1,669.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas MTD's P/E ratio is 38.40. In terms of profitability, FLGT's ROE is -0.08%, compared to MTD's ROE of -12.00%. Regarding short-term risk, FLGT is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
FLGT vs DGX Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, DGX has a market cap of 26.8B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while DGX trades at $242.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas DGX's P/E ratio is 23.96. In terms of profitability, FLGT's ROE is -0.08%, compared to DGX's ROE of +0.15%. Regarding short-term risk, FLGT is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
FLGT vs LH Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, LH has a market cap of 26.8B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while LH trades at $329.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas LH's P/E ratio is 19.58. In terms of profitability, FLGT's ROE is -0.08%, compared to LH's ROE of +0.12%. Regarding short-term risk, FLGT is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
FLGT vs GH Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, GH has a market cap of 23.2B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while GH trades at $173.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas GH's P/E ratio is -49.64. In terms of profitability, FLGT's ROE is -0.08%, compared to GH's ROE of +2.11%. Regarding short-term risk, FLGT is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
FLGT vs EXAS Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas EXAS's P/E ratio is -95.37. In terms of profitability, FLGT's ROE is -0.08%, compared to EXAS's ROE of -0.04%. Regarding short-term risk, FLGT is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
FLGT vs MEDP Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, MEDP has a market cap of 18.9B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while MEDP trades at $676.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas MEDP's P/E ratio is 39.67. In terms of profitability, FLGT's ROE is -0.08%, compared to MEDP's ROE of +1.00%. Regarding short-term risk, FLGT is less volatile compared to MEDP. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check MEDP's competition here
Revvity, Inc. (NYSE: RVTY)
FLGT vs RVTY Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, RVTY has a market cap of 17.9B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while RVTY trades at $160.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas RVTY's P/E ratio is 29.98. In terms of profitability, FLGT's ROE is -0.08%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, FLGT is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check RVTY's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
FLGT vs CRL Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, CRL has a market cap of 17.2B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while CRL trades at $357.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas CRL's P/E ratio is 36.07. In terms of profitability, FLGT's ROE is -0.08%, compared to CRL's ROE of -0.08%. Regarding short-term risk, FLGT is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check CRL's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
FLGT vs ILMNV Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas ILMNV's P/E ratio is N/A. In terms of profitability, FLGT's ROE is -0.08%, compared to ILMNV's ROE of N/A. Regarding short-term risk, FLGT is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check ILMNV's competition here
PerkinElmer, Inc. (NYSE: PKI)
FLGT vs PKI Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas PKI's P/E ratio is 41.45. In terms of profitability, FLGT's ROE is -0.08%, compared to PKI's ROE of +0.03%. Regarding short-term risk, FLGT is less volatile compared to PKI. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check PKI's competition here
ICON Public Limited Company (NASDAQ: ICLR)
FLGT vs ICLR Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, ICLR has a market cap of 14.2B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while ICLR trades at $183.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas ICLR's P/E ratio is 14.99. In terms of profitability, FLGT's ROE is -0.08%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, FLGT is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
FLGT vs QGEN Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, QGEN has a market cap of 10.4B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while QGEN trades at $50.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas QGEN's P/E ratio is 20.81. In terms of profitability, FLGT's ROE is -0.08%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, FLGT is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
FLGT vs GRAL Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, GRAL has a market cap of 6.2B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while GRAL trades at $139.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas GRAL's P/E ratio is -14.35. In terms of profitability, FLGT's ROE is -0.08%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, FLGT is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
FLGT vs RDNT Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, RDNT has a market cap of 5.5B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while RDNT trades at $70.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas RDNT's P/E ratio is 152.28. In terms of profitability, FLGT's ROE is -0.08%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, FLGT is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check RDNT's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
FLGT vs BLLN Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, BLLN has a market cap of 5.3B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while BLLN trades at $111.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas BLLN's P/E ratio is 159.24. In terms of profitability, FLGT's ROE is -0.08%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, FLGT is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check BLLN's competition here
Sotera Health Company (NASDAQ: SHC)
FLGT vs SHC Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while SHC trades at $18.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas SHC's P/E ratio is 19.16. In terms of profitability, FLGT's ROE is -0.08%, compared to SHC's ROE of +0.27%. Regarding short-term risk, FLGT is less volatile compared to SHC. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
FLGT vs SYNH Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas SYNH's P/E ratio is 61.40. In terms of profitability, FLGT's ROE is -0.08%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, FLGT is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
FLGT vs VCYT Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, VCYT has a market cap of 3.9B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while VCYT trades at $48.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas VCYT's P/E ratio is 24.10. In terms of profitability, FLGT's ROE is -0.08%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, FLGT is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
FLGT vs CDNA Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, CDNA has a market cap of 3.6B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while CDNA trades at $69.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas CDNA's P/E ratio is 82.26. In terms of profitability, FLGT's ROE is -0.08%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, FLGT is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
FLGT vs OLK Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas OLK's P/E ratio is -96.59. In terms of profitability, FLGT's ROE is -0.08%, compared to OLK's ROE of -0.07%. Regarding short-term risk, FLGT is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check OLK's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
FLGT vs NEO Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, NEO has a market cap of 2.2B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while NEO trades at $16.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas NEO's P/E ratio is 128.38. In terms of profitability, FLGT's ROE is -0.08%, compared to NEO's ROE of -0.06%. Regarding short-term risk, FLGT is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check NEO's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
FLGT vs WGS Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, WGS has a market cap of 1.8B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while WGS trades at $61.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas WGS's P/E ratio is 170.17. In terms of profitability, FLGT's ROE is -0.08%, compared to WGS's ROE of -0.39%. Regarding short-term risk, FLGT is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
FLGT vs PSNL Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while PSNL trades at $15.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas PSNL's P/E ratio is -14.57. In terms of profitability, FLGT's ROE is -0.08%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, FLGT is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
FLGT vs OPK Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while OPK trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas OPK's P/E ratio is -18.11. In terms of profitability, FLGT's ROE is -0.08%, compared to OPK's ROE of -0.06%. Regarding short-term risk, FLGT is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
FLGT vs CSTL Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, CSTL has a market cap of 1B. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while CSTL trades at $33.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas CSTL's P/E ratio is -50.45. In terms of profitability, FLGT's ROE is -0.08%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, FLGT is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check CSTL's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
FLGT vs GRALV Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas GRALV's P/E ratio is N/A. In terms of profitability, FLGT's ROE is -0.08%, compared to GRALV's ROE of N/A. Regarding short-term risk, FLGT is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check GRALV's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
FLGT vs MYGN Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, MYGN has a market cap of 575.8M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while MYGN trades at $6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas MYGN's P/E ratio is -46.31. In terms of profitability, FLGT's ROE is -0.08%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, FLGT is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
FLGT vs CO Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas CO's P/E ratio is 5.06. In terms of profitability, FLGT's ROE is -0.08%, compared to CO's ROE of +0.11%. Regarding short-term risk, FLGT is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
FLGT vs FLDM Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas FLDM's P/E ratio is -4.74. In terms of profitability, FLGT's ROE is -0.08%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, FLGT is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check FLDM's competition here
Exagen Inc. (NASDAQ: XGN)
FLGT vs XGN Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, XGN has a market cap of 181M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while XGN trades at $7.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas XGN's P/E ratio is -9.22. In terms of profitability, FLGT's ROE is -0.08%, compared to XGN's ROE of -1.22%. Regarding short-term risk, FLGT is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check XGN's competition here
Biodesix, Inc. (NASDAQ: BDSX)
FLGT vs BDSX Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, BDSX has a market cap of 173.1M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while BDSX trades at $21.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas BDSX's P/E ratio is -6.71. In terms of profitability, FLGT's ROE is -0.08%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, FLGT is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check BDSX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
FLGT vs GTH Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas GTH's P/E ratio is -1.11. In terms of profitability, FLGT's ROE is -0.08%, compared to GTH's ROE of -1.01%. Regarding short-term risk, FLGT is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
FLGT vs GENE Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas GENE's P/E ratio is -38.25. In terms of profitability, FLGT's ROE is -0.08%, compared to GENE's ROE of -1.85%. Regarding short-term risk, FLGT is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check GENE's competition here
Freenome, Inc. (NASDAQ: FRNM)
FLGT vs FRNM Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, FRNM has a market cap of 103.8M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while FRNM trades at $12.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas FRNM's P/E ratio is N/A. In terms of profitability, FLGT's ROE is -0.08%, compared to FRNM's ROE of N/A. Regarding short-term risk, FLGT is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check FRNM's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
FLGT vs IMDX Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, IMDX has a market cap of 98.2M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while IMDX trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas IMDX's P/E ratio is -2.01. In terms of profitability, FLGT's ROE is -0.08%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, FLGT is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check IMDX's competition here
Precipio, Inc. (NASDAQ: PRPO)
FLGT vs PRPO Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, PRPO has a market cap of 35M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while PRPO trades at $19.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas PRPO's P/E ratio is -30.08. In terms of profitability, FLGT's ROE is -0.08%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, FLGT is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check PRPO's competition here
Akumin Inc. (NASDAQ: AKU)
FLGT vs AKU Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas AKU's P/E ratio is -0.13. In terms of profitability, FLGT's ROE is -0.08%, compared to AKU's ROE of -5.32%. Regarding short-term risk, FLGT is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check AKU's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
FLGT vs QUCY Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, QUCY has a market cap of 19.4M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while QUCY trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas QUCY's P/E ratio is -0.04. In terms of profitability, FLGT's ROE is -0.08%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, FLGT is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
FLGT vs MDXH Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, MDXH has a market cap of 18.6M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while MDXH trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas MDXH's P/E ratio is -0.27. In terms of profitability, FLGT's ROE is -0.08%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, FLGT is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check MDXH's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
FLGT vs BIAF Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, BIAF has a market cap of 17.8M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while BIAF trades at $2.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas BIAF's P/E ratio is -0.33. In terms of profitability, FLGT's ROE is -0.08%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, FLGT is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check BIAF's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
FLGT vs CEMI Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas CEMI's P/E ratio is -0.63. In terms of profitability, FLGT's ROE is -0.08%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, FLGT is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
FLGT vs ENZ Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas ENZ's P/E ratio is -2.24. In terms of profitability, FLGT's ROE is -0.08%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, FLGT is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
FLGT vs PMD Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas PMD's P/E ratio is -5.24. In terms of profitability, FLGT's ROE is -0.08%, compared to PMD's ROE of -0.32%. Regarding short-term risk, FLGT is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
FLGT vs ME Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas ME's P/E ratio is -0.03. In terms of profitability, FLGT's ROE is -0.08%, compared to ME's ROE of -3.47%. Regarding short-term risk, FLGT is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
FLGT vs MYNZ Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, FLGT's ROE is -0.08%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, FLGT is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
FLGT vs BNR Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, BNR has a market cap of 11.8M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while BNR trades at $11.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas BNR's P/E ratio is -12.82. In terms of profitability, FLGT's ROE is -0.08%, compared to BNR's ROE of -0.13%. Regarding short-term risk, FLGT is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check BNR's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
FLGT vs CHEK Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas CHEK's P/E ratio is -0.43. In terms of profitability, FLGT's ROE is -0.08%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, FLGT is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
FLGT vs CNTG Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas CNTG's P/E ratio is -0.23. In terms of profitability, FLGT's ROE is -0.08%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, FLGT is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check CNTG's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
FLGT vs BIAFW Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, BIAFW has a market cap of 7.8M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while BIAFW trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas BIAFW's P/E ratio is 0.83. In terms of profitability, FLGT's ROE is -0.08%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, FLGT is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check BIAFW's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
FLGT vs NDRA Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, NDRA has a market cap of 7.3M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while NDRA trades at $4.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas NDRA's P/E ratio is -0.73. In terms of profitability, FLGT's ROE is -0.08%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, FLGT is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
FLGT vs APDN Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas APDN's P/E ratio is -0.10. In terms of profitability, FLGT's ROE is -0.08%, compared to APDN's ROE of -7.23%. Regarding short-term risk, FLGT is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
FLGT vs NVTA Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas NVTA's P/E ratio is -0.00. In terms of profitability, FLGT's ROE is -0.08%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, FLGT is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
FLGT vs LMDX Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas LMDX's P/E ratio is -0.01. In terms of profitability, FLGT's ROE is -0.08%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, FLGT is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
FLGT vs LMDXW Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, FLGT's ROE is -0.08%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, FLGT is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check LMDXW's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
FLGT vs ADVB Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, ADVB has a market cap of 4.7M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while ADVB trades at $2.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas ADVB's P/E ratio is -25.73. In terms of profitability, FLGT's ROE is -0.08%, compared to ADVB's ROE of +1.22%. Regarding short-term risk, FLGT is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check ADVB's competition here
DermTech, Inc. (NASDAQ: DMTK)
FLGT vs DMTK Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas DMTK's P/E ratio is -0.04. In terms of profitability, FLGT's ROE is -0.08%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, FLGT is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
FLGT vs NOTV Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas NOTV's P/E ratio is -0.03. In terms of profitability, FLGT's ROE is -0.08%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, FLGT is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
FLGT vs SQL Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas SQL's P/E ratio is -0.40. In terms of profitability, FLGT's ROE is -0.08%, compared to SQL's ROE of -30.46%. Regarding short-term risk, FLGT is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
FLGT vs AWH Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas AWH's P/E ratio is -0.09. In terms of profitability, FLGT's ROE is -0.08%, compared to AWH's ROE of +1.62%. Regarding short-term risk, FLGT is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check AWH's competition here
iSpecimen Inc. (NASDAQ: ISPC)
FLGT vs ISPC Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, ISPC has a market cap of 2.1M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while ISPC trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas ISPC's P/E ratio is -0.03. In terms of profitability, FLGT's ROE is -0.08%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, FLGT is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check ISPC's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
FLGT vs HTGM Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas HTGM's P/E ratio is -0.03. In terms of profitability, FLGT's ROE is -0.08%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, FLGT is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
FLGT vs BIOC Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas BIOC's P/E ratio is -0.01. In terms of profitability, FLGT's ROE is -0.08%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, FLGT is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
FLGT vs SQLLW Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, FLGT's ROE is -0.08%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, FLGT is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
FLGT vs WGSWW Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, FLGT's ROE is -0.08%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, FLGT is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check WGSWW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
FLGT vs CHEKZ Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, FLGT's ROE is -0.08%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, FLGT is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check CHEKZ's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
FLGT vs BNGOW Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas BNGOW's P/E ratio is N/A. In terms of profitability, FLGT's ROE is -0.08%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, FLGT is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check BNGOW's competition here
Danaher Corporation (NYSE: DHR-PA)
FLGT vs DHR-PA Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, FLGT's ROE is -0.08%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, FLGT is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check DHR-PA's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
FLGT vs MEUSW Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas MEUSW's P/E ratio is N/A. In terms of profitability, FLGT's ROE is -0.08%, compared to MEUSW's ROE of -3.47%. Regarding short-term risk, FLGT is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check MEUSW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
FLGT vs NDRAW Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas NDRAW's P/E ratio is N/A. In terms of profitability, FLGT's ROE is -0.08%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, FLGT is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check NDRAW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
FLGT vs OCDX Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas OCDX's P/E ratio is -42.28. In terms of profitability, FLGT's ROE is -0.08%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, FLGT is less volatile compared to OCDX. This indicates lower risk in terms of short-term price fluctuations for FLGT.Check OCDX's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
FLGT vs PRXL Comparison October 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FLGT stands at 556.4M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, FLGT is priced at $20.22 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FLGT currently has a P/E ratio of 2022.00, whereas PRXL's P/E ratio is 42.97. In terms of profitability, FLGT's ROE is -0.08%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, FLGT is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for FLGT.Check PRXL's competition here